Definium Prices Upsized $700M Offering at $34/Share Following Positive Phase 3 Data
DFTX has more than doubled off its 52-week low of $6.345 on elevated volume (2.5× avg).
Summary
Definium Therapeutics has priced its public offering, raising $700 million by selling 20.59 million shares at $34 each. This offering was upsized from the initially announced $500 million, indicating strong investor demand. The capital raise follows the company's recent announcement of highly positive Phase 3 results for its DT120 ODT drug. This significant funding will support the company's operations and potential commercialization efforts for DT120 ODT.
At the time of this announcement, DFTX was trading at $36.18 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.9B. The 52-week trading range was $6.35 to $39.16. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Reuters.